Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy.
Pompe disease is a lysosomal storage disorder caused by the deficiency of acid alpha-glucosidase, the enzyme that degrades glycogen in the lysosomes. The disease manifests as a fatal cardiomyopathy and skeletal muscle myopathy in infants; in milder late-onset forms skeletal muscle is the major tissue affected. We have previously demonstrated that autophagic inclusions in muscle are prominent in adult patients and the mouse model. In this study we have evaluated the contribution of the autophagic pathology in infants before and 6 months after enzyme replacement therapy. Single muscle fibers, isolated from muscle biopsies, were stained for autophagosomal and lysosomal markers and analyzed by confocal microscopy. In addition, unstained bundles of fixed muscles were analyzed by second harmonic imaging. Unexpectedly, the autophagic component which is so prominent in juvenile and adult patients was negligible in infants; instead, the overwhelming characteristic was the presence of hugely expanded lysosomes. After 6 months on therapy, however, the autophagic buildup becomes visible as if unmasked by the clearance of glycogen. In most fibers, the two pathologies did not seem to coexist. These data point to the possibility of differences in the pathogenesis of Pompe disease in infants and adults.
Raben
Nina
N
Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892-1820, USA. rabenn@mail.nih.gov
Ralston
Evelyn
E
Chien
Yin-Hsiu
YH
Baum
Rebecca
R
Schreiner
Cynthia
C
Hwu
Wuh-Liang
WL
Zaal
Kristien J M
KJ
Plotz
Paul H
PH
D000328:Adult; D001343:Autophagy / Q000502:physiology*; D002648:Child; D002675:Child, Preschool; D056947:Enzyme Replacement Therapy; D006009:Glycogen Storage Disease Type II / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008247:Lysosomes / Q000201:enzymology / Q000473:pathology*; D018485:Muscle Fibers, Skeletal / Q000473:pathology; D000520:alpha-Glucosidases / Q000172:deficiency / Q000378:metabolism / Q000627:therapeutic use
C509951:GAA protein, human; D000520:alpha-Glucosidases
J Pediatr. 2006 May;148(5):671-676
16737883
Cell. 2008 Jan 11;132(1):27-42
18191218
Pediatrics. 2008 Jul;122(1):e39-45
18519449
Pediatrics. 2003 Aug;112(2):332-40
12897283
Mol Ther. 2006 Dec;14(6):831-9
17008131
Autophagy. 2007 Nov-Dec;3(6):546-52
17592248
Biochim Biophys Acta. 2009 Apr;1793(4):684-96
19111581
J Neurol. 2010 Jan;257(1):91-7
19649685
J Cell Sci. 2004 Jun 1;117(Pt 13):2805-12
15169837
Annu Rev Genet. 2009;43:67-93
19653858
J Child Neurol. 2007 May;22(5):565-73
17690063
Mol Ther. 2005 Jan;11(1):48-56
15585405
Pediatr Res. 2009 Sep;66(3):329-35
19542901
Mol Genet Metab. 2010 Jan;99(1):26-33
19775921
Hum Mutat. 1998;11(4):306-12
9554747
J Neurol. 2008 Jun;255(6):831-8
18458862
N Engl J Med. 2010 Apr 15;362(15):1396-406
20393176
Genet Med. 2009 Mar;11(3):210-9
19287243
Neurology. 2007 Jan 9;68(2):99-109
17151339
Ann Neurol. 2004 Apr;55(4):495-502
15048888
Nature. 2008 Feb 28;451(7182):1069-75
18305538
Neurotherapeutics. 2008 Oct;5(4):569-78
19019308
Cell Death Differ. 2007 May;14(5):887-94
17332773
J Neurol. 2005 Aug;252(8):875-84
16133732
Ann Neurol. 2006 Apr;59(4):700-8
16532490
Genet Med. 2001 Mar-Apr;3(2):132-8
11286229
Pediatrics. 2009 Dec;124(6):e1116-25
19948615
J Struct Biol. 2008 Jun;162(3):500-8
18468456
Mol Genet Metab. 2003 Sep-Oct;80(1-2):159-69
14567965
Autophagy. 2008 Aug;4(6):740-3
18567941
Methods Enzymol. 2009;453:417-49
19216919
Virchows Arch B Cell Pathol Incl Mol Pathol. 1984;45(1):23-36
6199885
EMBO J. 2000 Nov 1;19(21):5720-8
11060023
J Pediatr. 2006 Jul;149(1):89-97
16860134
Lab Invest. 2006 Dec;86(12):1208-20
17075580